Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 4.8% – Should You Buy?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) shares shot up 4.8% during trading on Tuesday . The stock traded as high as $16.99 and last traded at $16.96. 250,970 shares changed hands during mid-day trading, a decline of 71% from the average session volume of 872,109 shares. The stock had previously closed at $16.19.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on GLUE. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Monte Rosa Therapeutics in a report on Monday. Jefferies Financial Group restated a “buy” rating and issued a $22.00 target price on shares of Monte Rosa Therapeutics in a research note on Wednesday, December 17th. Finally, Wells Fargo & Company lifted their price target on Monte Rosa Therapeutics from $10.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, November 7th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Monte Rosa Therapeutics has an average rating of “Hold” and an average price target of $17.75.

Monte Rosa Therapeutics Trading Up 7.0%

The stock has a market cap of $1.15 billion, a price-to-earnings ratio of 55.13 and a beta of 1.60. The firm has a fifty day simple moving average of $14.34 and a 200-day simple moving average of $8.66.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its earnings results on Thursday, November 6th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.06. Monte Rosa Therapeutics had a return on equity of 8.28% and a net margin of 11.54%.The company had revenue of $12.77 million during the quarter, compared to the consensus estimate of $7.37 million. On average, equities analysts predict that Monte Rosa Therapeutics, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. BVF Inc. IL boosted its stake in shares of Monte Rosa Therapeutics by 104.7% in the 1st quarter. BVF Inc. IL now owns 5,660,132 shares of the company’s stock valued at $26,263,000 after purchasing an additional 2,895,661 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Monte Rosa Therapeutics by 459.4% in the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock valued at $5,791,000 after buying an additional 1,054,406 shares during the period. Geode Capital Management LLC boosted its stake in Monte Rosa Therapeutics by 12.0% in the second quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company’s stock valued at $5,071,000 after acquiring an additional 120,098 shares during the last quarter. Marshall Wace LLP boosted its stake in Monte Rosa Therapeutics by 102.4% in the third quarter. Marshall Wace LLP now owns 902,834 shares of the company’s stock valued at $6,690,000 after acquiring an additional 456,754 shares during the last quarter. Finally, Vestal Point Capital LP acquired a new stake in Monte Rosa Therapeutics during the 3rd quarter worth $5,928,000. 79.96% of the stock is currently owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.